Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 8/20 | 0.55 |
| ▸ | INSR | P06213 | 6/20 | 0.54 |
| ▸ | NPM1 | P06748 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.49 |
| ▸ | IGF1R | P08069 | 4/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26778415 | 0.94 | ALK (0.58) | ALKINSREGFRMAP4K1IGF1R | |
| SCHEMBL26778417 | 0.92 | ALK (0.51) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL24328533 | 0.88 | ALK (0.49) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL26778523 | 0.88 | ALK (0.51) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL26778424 | 0.87 | ALK (0.57) | ALKINSREGFRMAP4K1IGF1R | |
| SCHEMBL24327505 | 0.87 | ALK (0.57) | ALKINSREGFRMAP4K1IGF1R | |
| SCHEMBL24327565 | 0.87 | EGFR (0.61) | ALKEGFRMAP4K1IGF1R | |
| SCHEMBL24327415 | 0.87 | ALK (0.57) | ALKEGFRMAP4K1IGF1RTTK | |
| SCHEMBL24327064 | 0.86 | IGF1R (0.54) | ALKMAP4K1IGF1RMAPK8MAPK10 | |
| SCHEMBL24327465 | 0.84 | IGF1R (0.52) | ALKMAP4K1IGF1RMAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ALK 13/4885INSR 82/4885NPM1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.